Introduction: There is no specific recommendation for the management of asymptomatic vaginal mesh erosions post antiincontinence or prolapse surgery, but revision or excision may represent overtreatment. We hypothesize that asymptomatic vaginal exposures remain asymptomatic during follow-up and do not require any intervention. Methods: We evaluated a “no treatment” approach by prospectively following-up women with asymptomatic vaginal exposures after antiincontinence and pelvic organ prolapse surgery. After a 1-month course of vaginal oestrogen, they underwent the “wait and see” protocol. It consisted of no treatment. Women were followed-up every 3 months, for the first year and then every 6 months with history, clinical examination with measurement of size of the exposure, and the evaluation of possible infection signs or vaginal discharge. Results: Forty women were followed-up for a median of 33.52 months (range 8–48 months). All exposures were ≤1 cm (mean 6.5 ± 1.5 mm, range 4–10 mm), patients were asymptomatic and without pain. During the observation period, the size of the exposure did not change and all women remained asymptomatic. Discussion/Conclusion: No treatment seems to be required for asymptomatic and small vaginal mesh exposures after prolapse or incontinence surgery.

Journal Section:
Original Paper
Keywords:
Mesh exposure, Sacrocolpopexy, Stress urinary incontinence surgery, Sling, Vaginal mesh
1.
Urogynecological surgical mesh: update on the safety and effectiveness of transvaginal placement for pelvic organ prolapse. Available from: http://fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm262435.htm.
2.
Altman D, Väyrynen T, Engh ME, Axelsen S, Falconer C; Nordic Transvaginal Mesh Group. Anterior colporrhaphy versus transvaginal mesh for pelvic-organ prolapse. N Engl J Med. 2011 May;364(19):1826–36.
3.
Boreham MK, Wai CY, Miller RT, Schaffer JI, Word RA. Morphometric analysis of smooth muscle in the anterior vaginal wall of women with pelvic organ prolapse. Am J Obstet Gynecol. 2002 Jul;187(1):56–63.
4.
Shah HN, Badlani GH. Mesh complications in female pelvic floor reconstructive surgery and their management: a systematic review. Indian J Urol. 2012 Apr;28(2):129–53.
5.
Zambon JP, Badlani GH. Vaginal mesh exposure presentation, evaluation, and management. Curr Urol Rep. 2016 Sep;17(9):65.
6.
MacDonald S, Terlecki R, Costantini E, Badlani G. Complications of transvaginal mesh for pelvic organ prolapse and stress urinary incontinence: tips for prevention, recognition, and management. Eur Urol Focus. 2016 Aug;2(3):260–7.
7.
Zambon JP, Badlani GH. Algorithm for management of vaginal mesh exposure. AUA News. 2016;21(1):1–5.
8.
Richter LA, Carter C, Gutman RE. Current role of mesh in vaginal prolapse surgery. Curr Opin Obstet Gynecol. 2014 Oct;26(5):409–14.
9.
Rouprêt M, Misraï V, Vaessen C, Cour F, Haertig A, Chartier-Kastler E. Laparoscopic surgical complete sling resection for tension-free vaginal tape-related complications refractory to first-line conservative management: a single-centre experience. Eur Urol. 2010 Aug;58(2):270–4.
10.
Pikaart DP, Miklos JR, Moore RD. Laparoscopic removal of pubovaginal polypropylene tension-free tape slings. JSLS. 2006 Apr-Jun;10(2):220–5.
11.
Macedo FI, O’Connor J, Mittal VK, Hurley P. Robotic removal of eroded vaginal mesh into the bladder. Int J Urol. 2013 Nov;20(11):1144–6.
12.
Haylen BT, Freeman RM, Swift SE, Cosson M, Davila GW, Deprest J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) & grafts in female pelvic floor surgery. Int Urogynecol J Pelvic Floor Dysfunct. 2011 Jan;22(1):3–15.
13.
Filocamo MT, Serati M, Li Marzi V, Costantini E, Milanesi M, Pietropaolo A, et al. The Female Sexual Function Index (FSFI): linguistic validation of the Italian version. J Sex Med. 2014 Feb;11(2):447–53.
14.
Srikrishna S, Robinson D, Cardozo L. Validation of the patient global impression of improvement (PGI-I) for urogenital prolapse. Int Urogynecol J Pelvic Floor Dysfunct. 2010 May;21(5):523–8.
15.
Barski D, Otto T, Gerullis H. Systematic review and classification of complications after anterior, posterior, apical, and total vaginal mesh implantation for prolapse repair. Surg Technol Int. 2014 Mar;24:217–24.
16.
Sweat SD, Itano NB, Clemens JQ, Bushman W, Gruenenfelder J, McGuire EJ, et al. Polypropylene mesh tape for stress urinary incontinence: complications of urethral erosion and outlet obstruction. J Urol. 2002 Jul;168(1):144–6.
17.
Costantini E, Zucchi A, Lazzeri M, Del Zingaro M, Vianello A, Porena M. Managing mesh erosion after abdominal pelvic organ prolapse repair: ten years’ experience in a single center. Urol Int. 2011;86(4):419–23.
18.
Kobashi KC, Govier FE. Management of vaginal erosion of polypropylene mesh slings. J Urol. 2003 Jun;169(6):2242–3.
19.
Update on serious complications associated with transvaginal placement of surgical mesh for pelvic organ prolapse: FDA safety communication. US Food and Drug Administration Web site [Accessed December 17, 2015]. Available from: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm262435.htm.
20.
FDA news release: FDA issues proposals to address risks associated with surgical mesh for transvaginal repair of pelvic organ prolapse. US Food and Drug Administration Web site [Accessed December 17, 2015]. 2015th transvaginal placement of surgical mesh for pelvic organ. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm395192.htm.
21.
Jha S, Cutner A, Moran P. The UK National Prolapse Survey: 10 years on. Int Urogynecol J Pelvic Floor Dysfunct. 2018 Jun;29(6):795–801.
22.
Chapple CR, Cruz F, Deffieux X, Milani AL, Arlandis S, Artibani W, et al. Consensus Statement of the European Urology Association and the European Urogynaecological Association on the use of implanted materials for treating pelvic organ prolapse and stress urinary incontinence. Eur Urol. 2017 Sep;72(3):424–31.
23.
Bailly GG, Carlson KV. The pubovaginal sling: reintroducing an old friend. Can Urol Assoc J. 2017 Jun;11(6Suppl 2):S147–51.
24.
Rehman H, Bezerra CC, Bruschini H, Cody JD. Traditional suburethral sling operations for urinary incontinence in women. Cochrane Database Syst Rev. 2011 Jan;1(1):CD001754.
25.
Albo ME, Richter HE, Brubaker L, Norton P, Kraus SR, Zimmern PE, et al.; Urinary Incontinence Treatment Network. Burch colposuspension versus fascial sling to reduce urinary stress incontinence. N Engl J Med. 2007 May;356(21):2143–55.
26.
Natale F, Illiano E, Marchesi A, La Penna C, Costantini E. Transobturator tape: over 10 years follow-up. Urology. 2019 Mar;pii:S0090-4295(19)30246-8.
27.
Natale F, Costantini E, La Penna C, Illiano E, Balsamo R, Carbone A, et al. Trocar-guided trans-vaginal mesh surgery for pelvic organ prolapse: effects on urinary continence and anatomical and functional outcomes. a prospective observational study. Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:29–34.
28.
Illiano E, Giannitsas K, Zucchi A, Di Biase M, Del Zingaro M, Bini V, et al. Sacrocolpopexy for posthysterectomy vaginal vault prolapse: long-term follow-up. Int Urogynecol J Pelvic Floor Dysfunct. 2016 Oct;27(10):1563–9.
29.
Costantini E, Mearini L, Bini V, Zucchi A, Mearini E, Porena M. Uterus preservation in surgical correction of urogenital prolapse. Eur Urol. 2005 Oct;48(4):642–9.
© 2019 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2019
You do not currently have access to this content.